Similarly, glycosides bearing a naphthopyrone group, such as Cassiaside (103) and Cassitoroside (104), behaved as weak inhibitors of PTP1B and α-glucosidase, suggesting that anthraquinone by itself represents a good scaffold for developing new MDLs for the treatment of T2D. Here, PTPN1 is linked to type 2 diabetes mellitus.